Total Payments
$837.13
2024 Payments
$140.69
Companies
11
Transactions
26
Medicare Patients
3,235
Medicare Billing
$714,529
Payment Breakdown by Category
Food & Beverage$764.49 (91.3%)
Education$72.64 (8.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $764.49 | 20 | 91.3% |
| Education | $72.64 | 6 | 8.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $169.25 | 7 | $0 (2023) |
| Bard Peripheral Vascular, Inc. | $147.02 | 1 | $0 (2022) |
| Otsuka America Pharmaceutical, Inc. | $130.26 | 3 | $0 (2019) |
| Relypsa, Inc. | $84.10 | 1 | $0 (2018) |
| AKEBIA THERAPEUTICS INC | $73.97 | 3 | $0 (2024) |
| NxStage Medical, Inc. | $66.36 | 1 | $0 (2019) |
| Travere Therapeutics, Inc. | $50.05 | 6 | $0 (2024) |
| BAXTER HEALTHCARE | $49.61 | 1 | $0 (2018) |
| Fresenius USA Marketing, Inc. | $23.41 | 1 | $0 (2022) |
| Bayer Healthcare Pharmaceuticals Inc. | $22.83 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $140.69 | 8 | AKEBIA THERAPEUTICS INC ($73.97) |
| 2023 | $73.25 | 6 | AstraZeneca Pharmaceuticals LP ($67.09) |
| 2022 | $188.27 | 3 | Bard Peripheral Vascular, Inc. ($147.02) |
| 2019 | $255.68 | 4 | Otsuka America Pharmaceutical, Inc. ($105.00) |
| 2018 | $158.97 | 4 | Relypsa, Inc. ($84.10) |
| 2017 | $20.27 | 1 | Keryx Biopharmaceuticals, Inc. ($20.27) |
All Payment Transactions
26 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/21/2024 | Travere Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $4.93 | General |
| 10/24/2024 | AKEBIA THERAPEUTICS INC | Auryxia (Drug), Vafseo | Food and Beverage | In-kind items and services | $24.75 | General |
| Category: Nephrology | ||||||
| 10/24/2024 | AKEBIA THERAPEUTICS INC | Vafseo (Drug) | Education | In-kind items and services | $24.61 | General |
| Category: Nephrology | ||||||
| 09/26/2024 | AKEBIA THERAPEUTICS INC | Vafseo (Drug) | Education | In-kind items and services | $24.61 | General |
| Category: Nephrology | ||||||
| 08/27/2024 | Travere Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $21.70 | General |
| 08/27/2024 | Travere Therapeutics, Inc. | — | Education | In-kind items and services | $16.89 | General |
| 08/27/2024 | Travere Therapeutics, Inc. | — | Education | In-kind items and services | $0.37 | General |
| 08/21/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $22.83 | General |
| Category: Cardio-renal | ||||||
| 11/01/2023 | Travere Therapeutics, Inc. | — | Education | In-kind items and services | $3.08 | General |
| 09/11/2023 | Travere Therapeutics, Inc. | — | Education | In-kind items and services | $3.08 | General |
| 07/18/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $18.17 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 05/23/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $17.51 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 03/01/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $18.49 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 01/03/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $12.92 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 06/10/2022 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $17.84 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 04/11/2022 | Fresenius USA Marketing, Inc. | Velphoro (Drug) | Food and Beverage | In-kind items and services | $23.41 | General |
| Category: Phosphate binder for ESRD | ||||||
| 02/17/2022 | Bard Peripheral Vascular, Inc. | — | Food and Beverage | In-kind items and services | $147.02 | General |
| Category: BD Interventional Peripheral Intervention | ||||||
| 08/22/2019 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $44.32 | General |
| 08/14/2019 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $40.00 | General |
| 06/13/2019 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $105.00 | General |
| Category: NEPHROLOGY | ||||||
| 04/11/2019 | NxStage Medical, Inc. | SYSTEM ONE (Device) | Food and Beverage | In-kind items and services | $66.36 | General |
| Category: Nephrology | ||||||
| 11/15/2018 | BAXTER HEALTHCARE | Renal - Non Product Related (Biological) | Food and Beverage | In-kind items and services | $49.61 | General |
| Category: Renal | ||||||
| 10/09/2018 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $11.02 | General |
| Category: NEPHROLOGY | ||||||
| 06/06/2018 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $14.24 | General |
| Category: NEPHROLOGY | ||||||
| 01/08/2018 | Relypsa, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $84.10 | General |
| Category: Hyperkalemia | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 720 | 1,588 | $489,412 | $137,400 |
| 2022 | 10 | 761 | 1,746 | $612,606 | $169,769 |
| 2021 | 11 | 748 | 1,961 | $668,417 | $199,899 |
| 2020 | 14 | 1,006 | 2,306 | $824,002 | $207,462 |
Total Patients
3,235
Total Services
7,601
Medicare Billing
$714,529
Procedure Codes
46
All Medicare Procedures & Services
46 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2023 | 32 | 158 | $150,100 | $40,604 | 27.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 193 | 575 | $91,425 | $33,297 | 36.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 187 | 380 | $88,540 | $22,076 | 24.9% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 112 | 134 | $43,014 | $12,675 | 29.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 56 | 119 | $26,894 | $10,297 | 38.3% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2023 | 20 | 32 | $30,400 | $6,793 | 22.3% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2023 | 35 | 78 | $28,470 | $4,103 | 14.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 31 | 31 | $11,904 | $3,449 | 29.0% |
| 90945 | Dialysis procedure including 1 evaluation | Facility | 2023 | 14 | 37 | $13,505 | $2,131 | 15.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 18 | 18 | $2,664 | $1,020 | 38.3% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 22 | 26 | $2,496 | $954.98 | 38.3% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2022 | 40 | 259 | $246,050 | $68,691 | 27.9% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 189 | 555 | $88,245 | $28,798 | 32.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 193 | 395 | $92,035 | $23,800 | 25.9% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 80 | 164 | $37,064 | $12,317 | 33.2% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 87 | 107 | $34,347 | $10,315 | 30.0% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2022 | 22 | 40 | $38,000 | $8,944 | 23.5% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 43 | 46 | $20,608 | $6,593 | 32.0% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2022 | 51 | 109 | $39,785 | $5,703 | 14.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 33 | 33 | $12,672 | $3,857 | 30.4% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2022 | 23 | 38 | $3,800 | $749.90 | 19.7% |
| 90960 | Dialysis services (4 or more physician visits per month), patient 20 years of age and older | Office | 2021 | 42 | 310 | $294,500 | $85,084 | 28.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 186 | 365 | $85,045 | $33,965 | 39.9% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 154 | 482 | $76,638 | $26,176 | 34.2% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 74 | 97 | $31,137 | $9,720 | 31.2% |
About Dr. David Choma, MD
Dr. David Choma, MD is a Nephrology healthcare provider based in Gallatin, Tennessee. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/04/2007. The National Provider Identifier (NPI) number assigned to this provider is 1447307251.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Choma, MD has received a total of $837.13 in payments from pharmaceutical and medical device companies, with $140.69 received in 2024. These payments were reported across 26 transactions from 11 companies. The most common payment nature is "Food and Beverage" ($764.49).
As a Medicare-enrolled provider, Choma has provided services to 3,235 Medicare beneficiaries, totaling 7,601 services with total Medicare billing of $714,529. Data is available for 4 years (2020–2023), covering 46 distinct procedure/service records.
Ad
Practice Information
- Specialty Nephrology
- Location Gallatin, TN
- Active Since 01/04/2007
- Last Updated 10/30/2025
- Taxonomy Code 207RN0300X
- Entity Type Individual
- NPI Number 1447307251
Products in Payments
- JYNARQUE (Drug) $130.26
- FARXIGA (Drug) $84.93
- Veltassa (Drug) $84.10
- SYSTEM ONE (Device) $66.36
- Renal - Non Product Related (Biological) $49.61
- Vafseo (Drug) $49.22
- Auryxia (Drug) $45.02
- Velphoro (Drug) $23.41
- Kerendia (Drug) $22.83
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.